Related Experiment Videos
S-nitrosoglutathione preserves platelet function during in vitro ventricular assist device circulation
Anna S Aledia1, Lisa M Tran, Bryan O King
1Department of Medicine, University of California Irvine Medical Center, Orange, USA.
ASAIO Journal (American Society for Artificial Internal Organs : 1992)
|September 26, 2002
Summary
S-nitrosoglutathione (GSNO) preserves platelet function during ventricular assist device (VAD) circulation. This study shows GSNO significantly inhibits platelet activation, reducing complications like bleeding and thromboembolism in VAD patients.
Area of Science:
- Biomedical Engineering
- Hematology
- Cardiovascular Research
Background:
- Ventricular assist devices (VADs) can cause severe bleeding and thromboembolism due to platelet dysfunction.
- Platelet activation during VAD circulation leads to impaired function.
Purpose of the Study:
- To investigate S-nitrosoglutathione (GSNO) as a potential agent to preserve platelet function during VAD circulation.
- To evaluate GSNO's ability to inhibit platelet activation and aggregation.
Main Methods:
- Dose-response studies of GSNO on platelet aggregation using an aggregometer.
- In vitro VAD circulation of human whole blood for 48 hours, with and without GSNO.
- Measurement of platelet aggregability and total nitrogen oxides (NO(T)) in perfusate over time.
Main Results:
- GSNO (1,000 microM) inhibited collagen and ristocetin-induced platelet aggregation by approximately 50%.
- In vitro VAD circulation showed GSNO preserved platelet aggregation for 12-24 hours, compared to controls (3-6 hours).
- GSNO maintained high perfusate NO(T) levels throughout the 48-hour circulation period.
Conclusions:
- GSNO effectively preserves platelet aggregation and function during in vitro VAD circulation.
- GSNO may be a titratable agent to inhibit platelet activation and reduce VAD-related complications in vivo.